Market Size of Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Market Size (2024) | USD 3.94 Billion |
Market Size (2029) | USD 5.25 Billion |
CAGR (2024 - 2029) | 5.90 % |
Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Analysis
The Europe Glucagon-Like Peptide-1 Agonists Market size is estimated at USD 3.94 billion in 2024, and is expected to reach USD 5.25 billion by 2029, growing at a CAGR of 5.90% during the forecast period (2024-2029).
mainly as a result of new drug launches. Europe has approximately 57 million adults living with diabetes, and this number is expected to reach 75 million by 2026, which would represent around 10% of the total population of Europe. Europe's expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway. Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.